Evidence map›Paper›PMID 35546373›Full record

ArticleJournal of gastroenterology2022

Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502.

Seiichiro Mitani, Ken Kato, Hiroyuki Daiko, Yoshinori Ito, Isao Nozaki, Takashi Kojima, Masahiko Yano, Satoru Nakagawa, Masaki Ueno, Masaya Watanabe and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Seiichiro MitaniDepartment of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. seiichiro.mitani@med.kindai.ac.jp.ORCID 0000-0003-0033-8741
Ken KatoDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki DaikoEsophageal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Yoshinori ItoDepartment of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
Isao NozakiDepartment of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Takashi KojimaDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Masahiko YanoDepartment of Surgery, Osaka International Cancer Institute, Osaka, Japan.
Satoru NakagawaDepartment of Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Masaki UenoDepartment of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan.
Masaya WatanabeDepartment of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Shigeru TsunodaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tetsuya AbeDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Tomohiro KadotaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Keita SasakiJapan Clinical Oncology Group Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Ryunosuke MachidaJapan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
National Cancer Center Hospital East · JPAichi Cancer Center · JPJapan Clinical Cancer Research Organization · JPKeio University · JPKyoto University · JPNiigata Cancer Center Hospital · JPOsaka International Cancer Institute · JPShikoku Cancer Center · JPShizuoka General Hospital · JPShowa University · JPToranomon Hospital · JP

Funding

National Cancer Center Research and Development Fund 2020-J-3
6 · The paper itself

Abstract

backgroundPrevious studies have suggested that patients with esophageal squamous cell carcinoma (ESCC) are still at a high risk of developing second primary malignancies (SPMs) after definitive therapies. We evaluated the development of SPMs and explored its risk factors in patients with clinical T1bN0 ESCC.

methodsJCOG0502 prospectively compared esophagectomy with definitive chemo-radiotherapy for clinical T1bN0 ESCC. Here, we reviewed all JCOG0502 patients' data for SPMs and investigated the risk factors for SPMs using uni-variable and multivariable analyses by Fine and Gray model.

resultsAmong 379 enrolled patients, 213 underwent esophagectomy and 166 received chemo-radiotherapy. Patient characteristics were male (85%); median age [63 (range 41-75) years; location of the primary tumor (upper/middle/lower thoracic esophagus, 11%/63%/27%, respectively]; alcohol consumption history (79%); smoking history (66%); prevalence of no/several/many/unknown Lugol-voiding lesions (LVLs) (45%/36%/8%/11%, respectively). In a median follow-up of 7.1 years, 118 SPMs occurred in 99 (26%) patients. Cumulative incidences of SPMs after 3, 5, and 10 years were 9%, 15%, and 36%, respectively. The most common primary tumor sites were the head and neck (35%), stomach (20%) and lungs (14%). In multivariable analyses, compared to no LVLs, several LVLs [hazard ratio (HR) 2.24, 95% confidential interval (CI) 1.32-3.81] and many LVLs (HR 2.88, 95% CI 1.27-6.52) were significantly associated with the development of SPMs. Sixteen patients died due to the SPMs.

conclusionThe incidence of SPMs was high. The presence of LVLs, which was a predictive factor for SPMs, may be useful for surveillance planning.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoplasms, Second PrimaryAdultAgedClinical Trials as TopicEsophagectomyFemaleHumansMaleMiddle AgedRetrospective StudiesDefinitive chemoradiotherapyEsophageal cancerEsophagectomySecond malignancies

Identifiers

PMID35546373
PMCPMC9232445
OpenAlexW4280607506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.